UK
Dr Andrew Thompson
I am a Principal in LCP’s Health Analytics team. Since completing my PhD in 2013, I have worked in clinical and genetic epidemiology at University College London and the University of Liverpool and have published >35 peer-reviewed journal articles.
I have extensive experience handling large datasets to answer questions relevant to disease susceptibility, drug utilization, and long-term health outcomes.
In addition, I have worked with colleagues in the UK's National Health Service (NHS) to implement and evaluate new tools/services with the aim of improving patient care and outcomes.
I am an active member of several international consortia that range in scope from genetic susceptibility of disease onset to guidelines for pharmacotherapy utilization.
Working with LCP feels like being part of a bigger team. The collaborative approach is a breath of fresh air compared with previous advisors.
LCP client
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
